Solid Biosciences Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Solid Biosciences Inc. (SLDB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 4.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-03-19
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2024-03-31 was 3.80%.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2023-09-30 was 4.20%.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2023-06-30 was 3.50%.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2025 was 4.00%, a 8.11% increase from fiscal 2024.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 3.70%, a 5.71% increase from fiscal 2023.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 3.50%, a 150.00% increase from fiscal 2022.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2022 was 1.40%, a 250.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.00% 10-K · filed 2026-03-19 | |||
| 2025-09-30 | 4.00% 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | 4.00% 10-Q · filed 2025-08-12 | |||
| 2024-12-31 | 3.70% 10-K · filed 2026-03-19 | |||
| 2024-09-30 | 3.70% 10-Q · filed 2025-11-03 | |||
| 2024-06-30 | 3.80% 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | 3.80% 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | 3.50% 10-K · filed 2025-03-06 | |||
| 2023-09-30 | 4.20% 10-Q · filed 2024-11-06 | 3.50% 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | 3.50% 10-Q · filed 2024-08-13 | 3.50% 10-Q · filed 2024-08-13 | ||
| 2022-12-31 | 1.40% 10-K · filed 2024-03-13 | |||
| 2021-12-31 | 0.40% 10-K · filed 2024-03-13 | |||
| 2020-12-31 | 0.60% 10-K · filed 2023-03-23 | |||
| 2019-12-31 | 1.50% 10-K · filed 2022-03-14 | |||
| 2018-12-31 | 2.60% 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |